Aclarion, Inc. (NASDAQ:ACON – Get Rating) was the recipient of a large decrease in short interest during the month of December. As of December 30th, there was short interest totalling 51,000 shares, a decrease of 7.8% from the December 15th total of 55,300 shares. Currently, 1.1% of the company's stock are sold short. Based on an average trading volume of 39,100 shares, the days-to-cover ratio is presently 1.3 days.

Aclarion Stock Up 1.6 %

ACON stock opened at $0.63 on Friday. Aclarion has a fifty-two week low of $0.38 and a fifty-two week high of $4.05. The firm's 50-day simple moving average is $0.65 and its 200 day simple moving average is $0.87.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aclarion stock. Captrust Financial Advisors bought a new stake in Aclarion, Inc. (NASDAQ:ACON – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 78,400 shares of the company's stock, valued at approximately $61,000. Captrust Financial Advisors owned about 1.00% of Aclarion as of its most recent SEC filing. Institutional investors and hedge funds own 2.02% of the company's stock.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software.

Further Reading

• Get a free copy of the StockNews.com research report on Aclarion (ACON)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.